Account Info
Log Out
English
Back
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh Refresh
Loading
History record delete
    Quotes All >
      News All >
        Log in to access Online Inquiry
        Back to the Top

        Update

        $Annovis Bio(ANVS.US)$ Annovis Bio (NYSE:ANVS) said the Data and Safety Monitoring Board has issued a positive recommendation for its Phase 2/3 study of its drug buntanetap in the treatment of mild-to-moderate Alzheimer’s disease.
        Annovis said the board found no drug-related Serious Adverse Events, and an Adverse Event rate of less than 5%. The dropout rate for the study was 4.7%.
        The company started the study in late March 2023.
        Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
        2
        +0
        Translate
        Report
        4153 Views
        Comment
        Sign in to post a comment
          avatar
          Influential mooer of October
          960Followers
          27Following
          9296Visitors
          Follow